Announcements Trials
Browse Landscape

Phase

Phase 2 42Phase 1 16Phase 3 14Phase 1/2 10Phase 2/3 6Phase 4 2Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Leukemia 1

Interventions

Cytarabine 34Cyclophosphamide 21Vincristine 20Methotrexate 18Dexamethasone 18Mercaptopurine 16Idarubicin 16nilotinib 15Daunorubicin 15Imatinib Mesylate 13fludarabine 12Granulocyte Colony-Stimulating Factor 12Asparaginase 12Rituximab 11Doxorubicin 10Prednisolone 9Etoposide 8Prednisone 7Thioguanine 6Teniposide 6Mitoxantrone 6Dasatinib 6venetoclax 5fludarabine phosphate 5Vindesine 5Stem Cell Transplantation 5Ifosfamide 5Azacitidine 4posaconazole 3pirtobrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Gemtuzumab × Other hematologic neoplasm × Clear all
NCT01041040 2013-07-31

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

PETHEMA Foundation

Phase 4 Completed
200 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00304447 2009-07-29

Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 4 Completed
30 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡